Form D · Biotechnology
Antibe Therapeutics Inc.
Toronto, A6 · CIK 0001583682
Offering snapshot reported Aug 29, 2019 · SEC filing
- Reported sold
- $283K Offering amount: $4.34M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 13, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 29, 2019 | Initial | $283,319 | No comparison | 1 | SEC filing |
| Aug 9, 2013 | Initial | $55,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $19.8K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-347707
The additional $4,054,599.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. The U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on 08/13/19, which was Cdn$1.3236=USD$1.00.
Each Unit consists of one common share and one-half of one common share purchase warrant. Each warrant is exercisable for one-half of one common share at an exercise price of $0.40 per common share for a period of 36 months.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| HAYWOOD SECURITIES (USA) INC. | 42072 | HAYWOOD SECURITIES INC. |
Source: Form D, filed Aug 29, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Bumby | Executive |
| Roderick Flower | Director |
| Jonathan Goodman | Director |
| Amal Khouri | Director |
| Daniel Legault | Director, Executive |
| Walt Macnee | Director |
| David Vaughan | Executive |
| John Wallace | Director |
| Alain Wilson | Executive |
| Yung Wu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
15 Prince Arthur Avenue
Toronto, A6, M5R 1B2
Toronto, A6, M5R 1B2